Antimicrobial Technology Found to Eliminate COVID-19 on Surfaces

0
28
When applied to a surface or incorporated into a material, BIOPROTECT™ forms a covalent bond with the substrate and creates a microbiostatic antimicrobial protective layer, making it unreceptive to microorganisms. The coating forms a nano-bed shield of spikes (self-assembling monolayer), each of which carry a positive charge that attracts the negatively charged microorganism. Once attracted, the molecular spikes pierce the cell and rupture its cell membrane, causing the microorganism to die. Image from ViaClean Technologies.

The Global Virus Network (GVN), a coalition comprised of the world’s preeminent human and animal virologists from 53 Centers of Excellence and 10 Affiliates in 32 countries, announced that two of its Centers of Excellence, the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia and the Rega Medical Research Institute of KU Leuven, Belgium, demonstrated that a BIOPROTECT™  formulation by ViaClean Technologies eradicates SARS-CoV-2 (the unique coronavirus that causes COVID-19) on surfaces and provides continuous residual viricidal activity for more than six weeks.  The announcement was made today by Dr. Christian Bréchot, President of the GVN.

The Doherty and Rega Institutes both used state-of-the-art high containment virology facilities to independently conduct extensive tests on a BIOPROTECT™ formulation to study its effects on SARS-CoV-2 infectivity on various surfaces.  The standard ASTM E1053 test methodology was adapted to assess SARS-CoV-2 viricidal efficacy of microbicides on environmental surfaces.  GVN scientists at the Doherty Institute under the direction of Prof. Damian Purcell, and at the Rega Institute under the direction of Prof. Johan Neyts, definitively demonstrated that the BIOPROTECT™ formulation eliminates SARS-CoV-2 by both reducing its ability to be infectious and by destroying its genomic material.

“Our studies on numerous antiseptic agents for surfaces contaminated with SARS-CoV-2 show that the BIOPROTECT™ formulation’s long-lasting activity is far superior to conventional decontamination agents in general use,” said Prof. Damian Purcell, Head of the Molecular Virology Laboratory in the Department of Microbiology and Immunology at The Peter Doherty Institute for Infection and Immunity at The University of Melbourne.  The Doherty Institute’s comprehensive report is expected to be available next week.

The tests were conducted in both “wet” and “dry” conditions.  In the wet test, SARS-CoV-2 was coated on stainless steel disks which were then treated with a wet solution of the BIOPROTECT™ formulation. In the dry test, the BIOPROTECT™ formulation was first applied to stainless steel samples which, 46 days later, were then exposed to a high titer of SARS-CoV-2.  Proving the longevity of the BIOPROTECT™ formulation on treated surfaces, tests revealed that the presence of the BIOPROTECT™ formulation maintained the ability to inactivate SARS-CoV-2 to negligible levels.  Furthermore, test results from Rega demonstrated that the disks pretreated with the BIOPROTECT™ formulation averaged a 99.7% inactivation of the SARS-CoV-2 virus.  All tests conducted were designed to conform with the United States Environmental Protection Agency (EPA) and equivalent standards of regulatory agencies in Europe and Australia, to ensure the acceptability and credibility of the results.

“We tested BIOPROTECT™ formulation and found that it eliminated 99.7% of the SARS-CoV-2 present, 46 days after the tested material was treated with BIOPROTECT™ formulation,” said Dr. Johan Neyts, Professor of Virology at the Rega Institute for Medical Research, KU Leuven.  “This product is unique and its long-lasting ability to eliminate SARS-CoV-2 far exceeds conventional disinfectants, which makes it very helpful in the battle against COVID-19.”  The Rega Institute’s report is accessible here.

“The results of the tests conducted by the Doherty and the Rega Institutes clearly demonstrate that BIOPROTECT™ eradicates SARS-CoV-2 on surfaces and provides continuous residual antimicrobial protection for an extended period of time,” said Dr. Bréchot.  “It is clear that effective antimicrobials will be extremely important in containing the COVID-19 pandemic, given the time it will take to implement mass vaccination and fully develop novel therapies.  In this context, we are not aware of any microbicide surface treatment that continuously prohibits the growth and surface transmissibility of SARS-CoV-2 for an extended period of time.  This represents a significant breakthrough in inhibiting the spread of COVID-19 by preventing surfaces from being contaminated by the virus and stopping the spread of the virus through contact with contaminated surfaces. Identifying and exploring innovative solutions, as well as fostering and facilitating collaboration between academic and industrial partners, be it large pharmaceutical firms or small biotech companies, is one of several ways the GVN can make a consequential contribution to the fight against COVID-19.”